MS
AXSM icon

Maven Securities’s Axsome Therapeutics AXSM Stock Holding History

Maven Securities’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7,500
Closed -$524K – 928
2023
Q3 		$524K Sell
7,500
-27,500
-79% -$2.06M 0.01% 797
2023
Q2 		$2.52M Buy
+35,000
New +$2.58M 0.04% 241
2022
Q1 		– Sell
-17,017
Closed -$643K – 966
2021
Q4 		$643K Buy
+17,017
New +$626K 0.02% 474
2021
Q3 		– Sell
-27,548
Closed -$1.94M – 1054
2021
Q2 		$1.94M Buy
+27,548
New +$1.65M 0.08% 244

Other funds holding AXSM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Maven Securities's AXSM Position: Q4 2023 in Review

Maven Securities sold out of Axsome Therapeutics (AXSM) in Q4 2023, closing a stake of 7,500 shares — an estimated $524K sold.

Maven Securities first reported a position in AXSM in Q2 2021 and held it in 4 quarters. The position peaked at $2.52M in Q2 2023. 244 funds tracked by Wall St. Rank hold AXSM as of Q4 2023.

  • Maven Securities reported no remaining Axsome Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Maven Securities sold 7,500 Axsome Therapeutics shares in Q4 2023, an estimated $524K.
  • Maven Securities first reported a position in Axsome Therapeutics in Q2 2021 and held it in 4 quarters.
  • Maven Securities's Axsome Therapeutics position peaked at $2.52M in Q2 2023.
  • 244 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2023.

Based on Maven Securities's 13F filing for Q4 2023, filed 12 Feb 2024.